Opinion
Video
Author(s):
Heather McArthur, MD, emphasizes the influence of recent and ongoing clinical trials, specifically DESTINY-Breast09 and HER2CLIMB-05, in steering the treatment paradigm in 1st-line HER2-positive metastatic breast cancer.
Pending Dato-DXd Approval Solidifies Importance of Sequencing in HR+ Breast Cancer
Bui and Kelly Discuss the Utility of Nab-Sirolimus in Advanced Malignant PEComa
Crofelemer Misses Diarrhea End Point in Patients With Solid Tumors Receiving Targeted Therapy
Paik Provides Insights Into Tepotinib Treatment in NSCLC Harboring MET Exon 14 Skipping Alterations
Enhanced Clinical Education and Simplified Guidelines Needed to Address Germline Testing Gaps in Breast Cancer
Research With ctDNA Continues to Pave the Way Toward Optimal Breast Cancer Management
Dr Rotow on the Impact of Biomarker Testing on NSCLC Treatment Outcomes
Dr Sabari on Barriers to Biomarker Testing in NSCLC
Dr Backhus on Surgical Eligibility in Borderline Resectable NSCLC
Dr Herbst on the Importance of Multidisciplinary Collaboration in NSCLC